DE69940265D1 - Alzheimersche krankheit sekretase - Google Patents

Alzheimersche krankheit sekretase

Info

Publication number: DE69940265D1
Authority: DE; Germany
Prior art keywords: alzheimersche; sekretase; disease; cleaving; assays
Prior art date: 1998-09-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69940265T

Other languages

English (en)

Inventor

Mark E Gurney

Michael Jerome Bienkowski

Robert Leroy Heinrikson

Luis A Parodi

Riqiang Yan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co LLC

Original Assignee

Pharmacia and Upjohn Co LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-24

Filing date

1999-09-23

Publication date

2009-02-26

1999-09-23 Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC

2009-02-26 Application granted granted Critical

2009-02-26 Publication of DE69940265D1 publication Critical patent/DE69940265D1/de

2019-09-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Neurology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE69940265T 1998-09-24 1999-09-23 Alzheimersche krankheit sekretase Expired - Lifetime DE69940265D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10159498P	1998-09-24	1998-09-24
PCT/US1999/020881 WO2000017369A2 (en)	1998-09-24	1999-09-23	Alzheimer's disease secretase

Publications (1)

Publication Number	Publication Date
DE69940265D1 true DE69940265D1 (de)	2009-02-26

Family

ID=22285461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69940265T Expired - Lifetime DE69940265D1 (de)	1998-09-24	1999-09-23	Alzheimersche krankheit sekretase

Country Status (28)

Country	Link
US (2)	US6835565B1 (de)
EP (1)	EP1115874B1 (de)
JP (3)	JP2002526081A (de)
KR (8)	KR20060111905A (de)
CN (4)	CN1502696A (de)
AT (1)	ATE420185T1 (de)
AU (2)	AU772812C (de)
BR (1)	BR9913920A (de)
CA (1)	CA2343004A1 (de)
CY (1)	CY1111006T1 (de)
CZ (1)	CZ2001966A3 (de)
DE (1)	DE69940265D1 (de)
DK (1)	DK1115874T3 (de)
EA (1)	EA009216B1 (de)
ES (1)	ES2318902T3 (de)
HK (1)	HK1042730B (de)
HU (1)	HUP0103838A3 (de)
IL (2)	IL142207A (de)
IS (1)	IS5905A (de)
NO (1)	NO20011505L (de)
NZ (2)	NZ510708A (de)
PL (1)	PL205294B1 (de)
PT (1)	PT1115874E (de)
SG (1)	SG113454A1 (de)
SK (1)	SK3902001A3 (de)
TR (3)	TR200601231T2 (de)
WO (1)	WO2000017369A2 (de)
ZA (1)	ZA200102387B (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9701684D0 (en)	1997-01-28	1997-03-19	Smithkline Beecham Plc	Novel compounds
AU1726199A (en)	1997-12-31	1999-07-19	Chiron Corporation	Metastatic cancer regulated gene
US6699671B1 (en) *	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
CN1502696A (zh)	1998-09-24	2004-06-09	��Ŷ��Լ��˾	阿尔茨海默氏疾病分泌酶
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7115410B1 (en) *	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
NZ534876A (en)	1999-02-10	2006-02-24	Elan Pharm Inc	Human beta-secretase enzyme, inhibitors and their compositions and uses
AU3770800A (en)	1999-03-26	2000-10-16	Amgen, Inc.	Beta secretase genes and polypeptides
AU5773500A (en)	1999-06-28	2001-01-31	Board Of Trustees Of The University Of Illinois, The	Inhibitors of memapsin 2 and use thereof
EP1496124A1 (de) *	1999-06-28	2005-01-12	Oklahoma Medical Research Foundation	Katalytisch wirksame rekombinierte Memapsin und Verfahren zur Verwendung davon
CA2397786A1 (en) *	1999-09-23	2001-04-05	Pharmacia & Upjohn Company	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US8273866B2 (en)	2002-02-20	2012-09-25	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
DE60124080T2 (de)	2000-03-23	2007-03-01	Elan Pharmaceuticals, Inc., San Francisco	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
MXPA02012560A (es)	2000-06-30	2003-05-14	Elan Pharm Inc	Compuestos para tratar la enfermedad de alzheimer.
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
US6686449B2 (en)	2000-06-30	2004-02-03	Pharmacia & Upjohn Company	Mutant presenilin 1 polypeptides
CA2410898A1 (en)	2000-07-19	2002-01-24	Pharmacia & Upjohn Company	Substrates and assays for .beta.-secretase activity
US20030190635A1 (en) *	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US7806980B2 (en)	2000-12-23	2010-10-05	Elan Pharmaceuticals, Inc.	Method for crystallizing human beta secretase in complex with an inhibitor
EP1434988A4 (de)	2001-02-23	2005-12-14	Elan Pharm Inc	Transgene bace-1-knockouts
US7524668B1 (en)	2001-05-10	2009-04-28	Elan Pharmaceuticals, Inc.	Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7517864B2 (en)	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2448253A1 (en)	2001-05-25	2002-11-28	Genset S.A.	Human cdnas and proteins and uses thereof
MXPA03011046A (es)	2001-06-01	2004-06-25	Elan Pharm Inc	Hidroxialquilaminas.
JP2005501015A (ja) *	2001-06-08	2005-01-13	イーラン　ファーマスーティカルズ、インコーポレイテッド	アルツハイマー病を治療する方法
AU2002315131A1 (en)	2001-06-13	2002-12-23	Elan Pharmaceuticals, Inc.	Aminediols as agents for the treatment of alzheimer's disease
US6982264B2 (en)	2001-06-27	2006-01-03	Elan Pharmaceuticals, Inc.	Substituted alcohols useful in treatment of Alzheimer's disease
CA2453447A1 (en)	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease
BR0211121A (pt)	2001-07-10	2004-10-26	Elan Pharm Inc	Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
MXPA04000338A (es)	2001-07-10	2004-07-23	Upjohn Co	Diamindioles para tratamiento de enfermedad de alzheimer.
US7186539B1 (en)	2001-08-31	2007-03-06	Pharmacia & Upjohn Company	Method for refolding enzymes
US7244755B2 (en)	2001-10-04	2007-07-17	Pharmacia & Upjohn Company	Hydroxypropylamines
CA2464736A1 (en)	2001-10-23	2003-05-15	Oklahoma Medical Research Foundation	Beta-secretase inhibitors and methods of use
EP1453789A2 (de)	2001-11-08	2004-09-08	Elan Pharmaceuticals, Inc.	N,n'-substituierte 1,3-diamino-2-hydroxypropanderivate
EP1458378B1 (de) *	2001-11-21	2006-05-24	Elan Pharmaceuticals, Inc.	Aminosäurederivate zur behandlung der alzheimer-krankheit
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP4272070B2 (ja)	2002-02-21	2009-06-03	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	修飾ｂａｃｅ
US7262208B2 (en)	2002-04-30	2007-08-28	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of Alzheimer's disease
US7442537B1 (en)	2002-05-10	2008-10-28	Elan Pharmaceuticals, Inc.	Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US7956176B2 (en)	2002-09-05	2011-06-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
UY27967A1 (es)	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
WO2004050609A1 (en)	2002-11-27	2004-06-17	Elan Pharmaceutical, Inc.	Substituted ureas and carbamates
US7521481B2 (en)	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
MXPA05011150A (es)	2003-04-21	2005-12-14	Elan Pharm Inc	2-hidroxi-3-diaminoalcanos de benzamida.
EP1473362A1 (de)	2003-05-02	2004-11-03	Elan Pharmaceuticals, Inc.	BACE Glykosylierungsvarianten
WO2005087751A2 (en)	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
JP2008505930A (ja)	2004-07-09	2008-02-28	エランファーマシューティカルズ，インコーポレイテッド	オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
CA2572775A1 (en)	2004-07-09	2006-01-26	Elan Pharmaceuticals, Inc.	Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
AU2006208226A1 (en)	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
AU2006223070B2 (en) *	2005-03-14	2012-02-09	High Point Pharmaceuticals, Llc	Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
EP1746092A1 (de)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
WO2007047305A1 (en)	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7838676B2 (en)	2005-11-21	2010-11-23	Amgen Inc.	Beta-secretase modulators and methods of use
US7872009B2 (en)	2005-11-21	2011-01-18	Amgen Inc.	Beta-Secretase modulators and methods of use
US7745484B2 (en)	2005-11-21	2010-06-29	Amgen Inc.	Beta-secretase modulators and methods of use
US20070292895A1 (en) *	2006-05-19	2007-12-20	Xiao-Ping Shi	Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
EP1865326B1 (de) *	2006-06-08	2011-09-07	FU Berlin	Assay zur Diagnose von Alzheimer basierend auf der Bestimmung des Verhältnisses von Sekretase-Aß-Spaltprodukten
TW200815349A (en)	2006-06-22	2008-04-01	Astrazeneca Ab	New compounds
EP2167471B1 (de)	2007-05-25	2013-10-16	Amgen Inc.	Substituierte hydroxyethylaminverbindungen als modulatoren von beta-sekretase und anwendungsverfahren
TW200901991A (en)	2007-05-25	2009-01-16	Amgen Inc	Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CA2687750C (en)	2007-07-06	2016-10-18	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
US7803809B2 (en)	2008-11-12	2010-09-28	Amgen Inc.	Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
TWI385175B (zh) *	2008-09-11	2013-02-11	Amgen Inc	作為β-分泌酶調節劑之螺旋-三環化合物及其使用方法
TW201020244A (en)	2008-11-14	2010-06-01	Astrazeneca Ab	New compounds
EP2281824A1 (de)	2009-08-07	2011-02-09	Noscira, S.A.	Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
WO2011063272A1 (en)	2009-11-23	2011-05-26	Amgen Inc.	Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063233A1 (en)	2009-11-23	2011-05-26	Amgen Inc.	Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8735384B2 (en)	2010-01-19	2014-05-27	Amgen Inc.	Amino heteroaryl compounds as beta-secretase modulators and methods of use
JP5584352B2 (ja)	2010-03-15	2014-09-03	アムジエン・インコーポレーテツド	β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
CA2791281A1 (en)	2010-03-15	2011-09-22	Amgen Inc.	Spiro-tetracyclic ring compounds as beta-secretase modulators
WO2012019056A1 (en)	2010-08-05	2012-02-09	Amgen Inc.	Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
JP6250394B2 (ja)	2010-08-19	2017-12-20	バック・インスティテュート・フォー・リサーチ・オン・エイジング	軽度の認知障害（ｍｃｉ）および関連障害の処置方法
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US9284296B2 (en)	2010-11-22	2016-03-15	Aubergine Pharmaceuticals Llc	Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
EP2643325A1 (de)	2010-11-23	2013-10-02	Amgen Inc.	Spiro-amino-imidazolon- und spiro-amino-dihydro-pyrimidinonverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
EP2673279A1 (de)	2011-02-07	2013-12-18	Amgen Inc.	5-amino-oxazepin- und 5-amino-thiazepanverbindungen als beta-sekretase-antagonisten und verwendungsverfahren
EP2675810A1 (de)	2011-02-15	2013-12-25	Amgen Inc.	Spiro-amino-imidazo-kondensierte heterocyclische verbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
JP2014526560A (ja)	2011-09-21	2014-10-06	アムジエン・インコーポレーテツド	β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
CN104270945B (zh)	2012-03-19	2017-03-29	巴克老龄化研究所	App特异性bace抑制剂(asbi)及其用途
WO2014059185A1 (en)	2012-10-12	2014-04-17	Amgen Inc.	Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
WO2014078314A1 (en)	2012-11-15	2014-05-22	Amgen Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9309263B2 (en)	2013-01-29	2016-04-12	Amgen Inc.	Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
WO2014127042A1 (en)	2013-02-12	2014-08-21	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
MX366855B (es)	2013-03-01	2019-07-26	Amgen Inc	Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
EP2964644B1 (de)	2013-03-08	2018-12-26	Amgen, Inc.	Perfluorierte cyclopropylfusionierte 1,3-oxazin-2-amin-verbindungen als beta-sekretase-hemmer und verfahren zur verwendung
US9096615B2 (en)	2013-07-30	2015-08-04	Amgen Inc.	Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
KR101791296B1 (ko)	2014-04-17	2017-10-27	제주대학교 산학협력단	알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주
US9550762B2 (en)	2014-08-08	2017-01-24	Amgen, Inc.	Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
KR20180012274A (ko) *	2015-04-30	2018-02-05	지앙수 누오-베타 파마수티칼 테크놀로지 컴퍼니, 리미티드	알츠하이머 질환을 치료하는데 사용되는 약물 및 치료 표적제를 스크리닝하는 방법
WO2017024180A1 (en)	2015-08-06	2017-02-09	Amgen Inc.	Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2017035529A1 (en)	2015-08-27	2017-03-02	Nantneuro, Llc	Compositions for app-selective bace inhibition and uses therfor
CN109563089B (zh)	2016-05-12	2023-06-16	巴克老年研究所	促进app正常加工的化合物
CA3047286A1 (en)	2016-12-15	2018-06-21	Amgen Inc.	Oxazine derivatives as beta-secretase inhibitors and methods of use
WO2018112094A1 (en)	2016-12-15	2018-06-21	Amgen Inc.	1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
MX386618B (es)	2016-12-15	2025-03-19	Amgen Inc	Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
AU2017376444B2 (en)	2016-12-15	2021-09-30	Amgen Inc.	Thiazine derivatives as beta-secretase inhibitors and methods of use
MA54101A (fr)	2016-12-15	2021-10-27	Amgen Inc	Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
CN107576785A (zh) *	2017-08-25	2018-01-12	广州市雷德生物科技有限公司	一种样本处理液及其应用
GB201803010D0 (en) *	2018-02-26	2018-04-11	Royal Holloway & Bedford New College	Neurodegenerative disorders
US12352719B2 (en)	2019-09-20	2025-07-08	KYCERA AVX Components Corporation	Somatic cell-based electrical biosensor
CN111518793A (zh) *	2020-05-20	2020-08-11	谭骏	年轻人血源APPα-分泌酶在阿尔茨海默病中的应用
CN114480494B (zh) *	2022-02-10	2024-07-05	中国科学技术大学	蛋白探针以及其在检测bace1活性中的应用
CN116829956A (zh) *	2023-02-28	2023-09-29	湖南乾康科技有限公司	用于检测蛋白生物标志物组的抗体在制备诊断ad、mci和其它类型老年痴呆的试剂盒中的用途
CN118831181B (zh) *	2024-09-20	2025-02-11	江苏集萃药康生物科技股份有限公司	一种三突变阿尔兹海默症小鼠模型的构建方法及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5200339A (en)	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
US5292652A (en)	1990-10-05	1994-03-08	Athena Neurosciences, Inc.	Amyloidin protease and uses thereof
US5877015A (en)	1991-01-21	1999-03-02	Imperial College Of Science, Technology Of Medicine	APP770 mutant in alzheimer's disease
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
TW327194B (en) *	1992-05-01	1998-02-21	American Cyanamid Co	Novel amyloid precursor proteins and methods of using same
WO1994013319A1 (en)	1992-12-16	1994-06-23	Miles Inc.	Cathepsin d is an amyloidogenic protease in alzheimer's disease
IL105793A0 (en)	1992-05-28	1993-09-22	Lilly Co Eli	Protease and related dna compounds
US5455169A (en)	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US5766846A (en)	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
US5605811A (en) *	1992-10-26	1997-02-25	Athena Neurosciences, Inc.	Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
EP0608546A3 (en) *	1992-12-22	1995-09-27	Takeda Chemical Industries Ltd	Glia activating factor (gaf), antibodies against it and their uses.
EP1308461A3 (de)	1993-01-25	2004-02-11	Takeda Chemical Industries, Ltd.	Antikörper gegen Beta-Amyloiden oder deren Abarten, und deren Verwendungen
ATE198622T1 (de)	1993-10-27	2001-01-15	Elan Pharm Inc	Transgene tiere, die app allele mit der schwedischen mutation beherbergen
US6211428B1 (en)	1994-09-01	2001-04-03	Merck & Co., Inc.	Transgenic mouse expressing a familial form of human amyloid precursor protein
US6093397A (en)	1995-04-04	2000-07-25	Eli Lilly And Company	Amyloid precursor protein protease
US5744346A (en)	1995-06-07	1998-04-28	Athena Neurosciences, Inc.	β-secretase
JPH11507538A (ja) *	1995-06-07	1999-07-06	アテナニューロサイエンシズインコーポレイティド	β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6221645B1 (en)	1995-06-07	2001-04-24	Elan Pharmaceuticals, Inc.	β-secretase antibody
DE19641180A1 (de)	1996-09-24	1998-03-26	Schering Ag	Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
WO1998021589A1 (en)	1996-11-15	1998-05-22	The Trustees Of The University Of Pennsylvania	Screening for modulators of amyloid processing
AU1684097A (en) *	1996-12-11	1998-07-03	Athena Neurosciences, Inc.	Beta-secretase isolated from human 293 cells
EP0848062A3 (de) *	1996-12-14	2000-07-05	Smithkline Beecham Corporation	Aspartylprotease ASP1
GB9626022D0 (en)	1996-12-14	1997-01-29	Smithkline Beecham Plc	Novel compounds
GB9701684D0 (en)	1997-01-28	1997-03-19	Smithkline Beecham Plc	Novel compounds
GB9721094D0 (en) *	1997-10-03	1997-12-03	Unilever Plc	Autophobic hairspray compositions
JP2002508182A (ja)	1997-12-17	2002-03-19	ジェンセット	分泌タンパク質の伸長ｃＤＮＡ
AU1726199A (en) *	1997-12-31	1999-07-19	Chiron Corporation	Metastatic cancer regulated gene
ES2312205T3 (es) *	1998-03-10	2009-02-16	Genentech, Inc.	Nuevo polipeptido y acidos nucleicos que lo codifican.
WO1999064587A1 (fr)	1998-06-05	1999-12-16	Aventis Pharma S.A.	Polypeptides possedant une activite de type beta-secretase
US6699671B1 (en)	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
CN1502696A (zh)	1998-09-24	2004-06-09	��Ŷ��Լ��˾	阿尔茨海默氏疾病分泌酶
US6844148B1 (en)	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6245884B1 (en)	1998-10-16	2001-06-12	Vivian Y. H. Hook	Secretases related to alzheimer's dementia
US6313268B1 (en)	1998-10-16	2001-11-06	Vivian Y. H. Hook	Secretases related to Alzheimer's dementia
NZ534876A (en) *	1999-02-10	2006-02-24	Elan Pharm Inc	Human beta-secretase enzyme, inhibitors and their compositions and uses
DE19910108C2 (de)	1999-03-08	2001-02-22	Falk Fahrenholz	Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie
AU3770800A (en)	1999-03-26	2000-10-16	Amgen, Inc.	Beta secretase genes and polypeptides
AU4640600A (en)	1999-05-11	2000-11-21	Eli Lilly And Company	Amyloid precursor protein protease and related nucleic acid compounds
US7087399B1 (en)	1999-05-13	2006-08-08	Scios, Inc.	β-secretase and modulation of β-secretase activity
AU5773500A (en)	1999-06-28	2001-01-31	Board Of Trustees Of The University Of Illinois, The	Inhibitors of memapsin 2 and use thereof
GB9924957D0 (en)	1999-10-21	1999-12-22	Smithkline Beecham Plc	Novel treatment
GB9925136D0 (en)	1999-10-22	1999-12-22	Smithkline Beecham Plc	Novel treatment
US6361975B1 (en)	1999-11-16	2002-03-26	Smithkline Beecham Corporation	Mouse aspartic secretase-2(mASP-2)
US6291223B1 (en)	1999-11-23	2001-09-18	Smithkline Beecham Corporation	Mouse aspartic secretase-1 (mASP1)

1999
- 1999-09-23 CN CNA2003101196641A patent/CN1502696A/zh active Pending
- 1999-09-23 EP EP99948189A patent/EP1115874B1/de not_active Expired - Lifetime
- 1999-09-23 KR KR1020067020982A patent/KR20060111905A/ko not_active Withdrawn
- 1999-09-23 KR KR1020067025867A patent/KR20070004143A/ko not_active Abandoned
- 1999-09-23 DK DK99948189T patent/DK1115874T3/da active
- 1999-09-23 NZ NZ510708A patent/NZ510708A/en not_active IP Right Cessation
- 1999-09-23 JP JP2000574268A patent/JP2002526081A/ja active Pending
- 1999-09-23 NZ NZ527053A patent/NZ527053A/xx not_active IP Right Cessation
- 1999-09-23 KR KR1020047015171A patent/KR100768381B1/ko not_active Expired - Fee Related
- 1999-09-23 KR KR1020047015172A patent/KR100691601B1/ko not_active Expired - Fee Related
- 1999-09-23 KR KR1020077000411A patent/KR20070013361A/ko not_active Withdrawn
- 1999-09-23 TR TR2006/01231T patent/TR200601231T2/xx unknown
- 1999-09-23 WO PCT/US1999/020881 patent/WO2000017369A2/en not_active Ceased
- 1999-09-23 US US09/806,194 patent/US6835565B1/en not_active Expired - Fee Related
- 1999-09-23 DE DE69940265T patent/DE69940265D1/de not_active Expired - Lifetime
- 1999-09-23 CN CNA2003101196637A patent/CN1502692A/zh active Pending
- 1999-09-23 ES ES99948189T patent/ES2318902T3/es not_active Expired - Lifetime
- 1999-09-23 AU AU61418/99A patent/AU772812C/en not_active Ceased
- 1999-09-23 HK HK02104092.7A patent/HK1042730B/zh not_active IP Right Cessation
- 1999-09-23 EA EA200100387A patent/EA009216B1/ru not_active IP Right Cessation
- 1999-09-23 CN CNB99811202XA patent/CN1198936C/zh not_active Expired - Fee Related
- 1999-09-23 TR TR2002/00662T patent/TR200200662T2/xx unknown
- 1999-09-23 CN CNB2003101196656A patent/CN1300320C/zh not_active Expired - Fee Related
- 1999-09-23 KR KR1020047015170A patent/KR100866676B1/ko not_active Expired - Fee Related
- 1999-09-23 AT AT99948189T patent/ATE420185T1/de active
- 1999-09-23 CZ CZ2001966A patent/CZ2001966A3/cs unknown
- 1999-09-23 PT PT99948189T patent/PT1115874E/pt unknown
- 1999-09-23 PL PL348629A patent/PL205294B1/pl not_active IP Right Cessation
- 1999-09-23 KR KR1020017003744A patent/KR100839284B1/ko not_active Expired - Fee Related
- 1999-09-23 CA CA002343004A patent/CA2343004A1/en not_active Abandoned
- 1999-09-23 BR BR9913920-0A patent/BR9913920A/pt not_active Application Discontinuation
- 1999-09-23 HU HU0103838A patent/HUP0103838A3/hu unknown
- 1999-09-23 TR TR2001/01484T patent/TR200101484T2/xx unknown
- 1999-09-23 KR KR1020067023390A patent/KR20060126626A/ko not_active Withdrawn
- 1999-09-23 SK SK390-2001A patent/SK3902001A3/sk unknown
- 1999-09-23 SG SG200301440A patent/SG113454A1/en unknown
2001
- 2001-03-22 IL IL142207A patent/IL142207A/en not_active IP Right Cessation
- 2001-03-22 IS IS5905A patent/IS5905A/is unknown
- 2001-03-22 ZA ZA200102387A patent/ZA200102387B/en unknown
- 2001-03-23 NO NO20011505A patent/NO20011505L/no not_active Application Discontinuation
2004
- 2004-08-04 AU AU2004203588A patent/AU2004203588B2/en not_active Ceased
- 2004-09-14 US US10/940,867 patent/US7812123B2/en not_active Expired - Lifetime
2007
- 2007-03-20 IL IL182070A patent/IL182070A0/en not_active IP Right Cessation
- 2007-12-12 JP JP2007320832A patent/JP2008113665A/ja not_active Withdrawn
2009
- 2009-02-18 CY CY20091100178T patent/CY1111006T1/el unknown
- 2009-06-10 JP JP2009139454A patent/JP2009201517A/ja active Pending

Also Published As

Publication number	Publication date
HUP0103838A2 (hu)	2002-03-28
US7812123B2 (en)	2010-10-12
KR20040099362A (ko)	2004-11-26
AU6141899A (en)	2000-04-10
IL182070A0 (en)	2007-07-24
KR100866676B1 (ko)	2008-11-11
KR100768381B1 (ko)	2007-10-18
HK1042730A1 (en)	2002-08-23
ES2318902T3 (es)	2009-05-01
CY1111006T1 (el)	2015-06-11
WO2000017369B1 (en)	2000-12-28
CA2343004A1 (en)	2000-03-30
KR100691601B1 (ko)	2007-03-09
KR20060111905A (ko)	2006-10-30
AU772812C (en)	2004-12-09
ATE420185T1 (de)	2009-01-15
KR20070013361A (ko)	2007-01-30
CN1502696A (zh)	2004-06-09
CZ2001966A3 (cs)	2001-10-17
KR20070004143A (ko)	2007-01-05
PL205294B1 (pl)	2010-03-31
CN1502697A (zh)	2004-06-09
PT1115874E (pt)	2009-04-09
NZ527053A (en)	2005-04-29
SG113454A1 (en)	2005-08-29
KR20010085837A (ko)	2001-09-07
NO20011505L (no)	2001-05-23
KR20040097216A (ko)	2004-11-17
KR20060126626A (ko)	2006-12-07
CN1339066A (zh)	2002-03-06
DK1115874T3 (da)	2009-04-20
AU772812B2 (en)	2004-05-06
JP2008113665A (ja)	2008-05-22
HUP0103838A3 (en)	2006-05-29
JP2009201517A (ja)	2009-09-10
KR20040093193A (ko)	2004-11-04
EP1115874B1 (de)	2009-01-07
HK1042730B (zh)	2005-11-18
EP1115874A2 (de)	2001-07-18
HK1062187A1 (en)	2004-10-21
CN1502692A (zh)	2004-06-09
US6835565B1 (en)	2004-12-28
JP2002526081A (ja)	2002-08-20
EA200100387A1 (ru)	2001-10-22
CN1300320C (zh)	2007-02-14
PL348629A1 (en)	2002-06-03
ZA200102387B (en)	2002-09-23
WO2000017369A2 (en)	2000-03-30
KR100839284B1 (ko)	2008-06-17
EA009216B1 (ru)	2007-12-28
BR9913920A (pt)	2001-11-06
TR200101484T2 (tr)	2002-06-21
AU2004203588A1 (en)	2004-09-02
NO20011505D0 (no)	2001-03-23
US20050026256A1 (en)	2005-02-03
TR200200662T2 (tr)	2002-06-21
AU2004203588B2 (en)	2007-11-22
WO2000017369A3 (en)	2000-11-23
NZ510708A (en)	2003-12-19
IL142207A (en)	2010-11-30
TR200601231T2 (tr)	2006-09-21
CN1198936C (zh)	2005-04-27
IS5905A (is)	2001-03-22
SK3902001A3 (en)	2001-12-03

Publication	Publication Date	Title
DE69940265D1 (de)	2009-02-26	Alzheimersche krankheit sekretase
WO2001049097A3 (en)	2003-11-20	Alzheimer's disease secretase, app substrates therefor, and uses therefor
TW200745552A (en)	2007-12-16	HU-ASP 1 protease substrate and uses thereof
ATE352638T1 (de)	2007-02-15	REVERSE ßTWO-HYBRIDß-SYSTEME
BR9813608B1 (pt)	2011-11-01	célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
WO2002006457A3 (en)	2002-10-17	Novel lipase genes
CA2263713A1 (en)	1999-01-07	Lyophilization of cultured human cells to preserve rna and dna
TR199802503A3 (tr)	1999-06-21	Endojen gen aktivasyonu için hücrelerin optimizasyonu.
WO1999025878A3 (en)	1999-10-28	Methods for modulating and identifying cellular senescence
WO2000009677A3 (en)	2000-06-15	Sterol-regulated site-1 protease and assays of modulators thereof
DE69928395D1 (de)	2005-12-22	Cyclin-e2 proteine und dafür kodierende gene
AU2900400A (en)	2000-09-28	Intact cell assay for protein tyrosine phosphatases
WO2001064912A3 (en)	2002-05-10	Triazine degrading enzymes
WO2002026929A3 (en)	2002-06-13	Kini-3 motor protein and methods for its use
NO20003880D0 (no)	2000-07-28	Transfekterende midler som er sensitive overfor reduserende betingelser, farmasøytiske preparater inneholdende disse samt deres anvendelser
DE60044038D1 (de)	2010-04-29	Xylosyltransferase und isoformen
WO1999047673A3 (en)	1999-11-18	Isolated mammalian membrane protein genes and related reagents
WO2001066709A3 (en)	2002-05-16	Sphingomyelinase enzymes and uses relating thereto
WO2002074921A3 (en)	2004-02-26	Methods for isolating proteins expressed by dendritic cells
CY1110496T1 (el)	2015-04-29	Σεκρεταση νοσου alzheimer, υποστρωματα app αυτης, και χρησεις αυτης
WO2002050243A3 (en)	2003-10-30	The use of ecm degrading enzymes for the improvement of cell transplantation
GB2289125A (en)	1995-11-08	Methods of assaying data-repairing enzymes and their alkylated derivatives
ECSP003672A (es)	2001-04-23	Secretasa en la enfermedad de alzheimer, substratos de la app y sus usos
DK1141337T3 (da)	2011-03-14	Gram-positive bakterier, som mangler HtrA-proteaseaktivitet, samt deres anvendelser
TH51992A (th)	2002-07-16	ซีครีเทสของโรคแอลซ์ไฮม์เมอร์ app สับสเตรทของมัน และการใช้งานของมัน

Legal Events

Date	Code	Title	Description
2010-01-28	8364	No opposition during term of opposition